Dynein axonemal heavy chain 6 (DNAH6)
Homo sapiens — UniProt Q9C0G6
Gene: DNAH6Homo sapiensSwissProt reviewed
Data last refreshed: (UniProt release unknown)
Key facts
Dynein axonemal heavy chain 6 (DNAH6) is a protein from Homo sapiens identified by UniProt accession Q9C0G6, 4158 residues long. MolForge cross-references it against 0 known binders and 43 disease associations.
- UniProt accession: Q9C0G6; gene symbol DNAH6.
- Organism: Homo sapiens.
- Length: 4158 amino acids.
- Top disease associations (Open Targets): Parkinson disease, multiple sclerosis and lysosomal storage disease.
- 3D structure: AlphaFold model available.
Target properties
| Protein name | Dynein axonemal heavy chain 6 |
|---|---|
| UniProt accession | Q9C0G6 |
| Gene | DNAH6 |
| Organism | Homo sapiens |
| Length | 4158 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | — |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|---|
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (43)
Diseases linked to this target (Open Targets).
- Parkinson disease · score 0.28
- multiple sclerosis · score 0.28
- lysosomal storage disease · score 0.28
- neurodegenerative disease · score 0.28
- Alzheimer disease · score 0.28
- ciliary dyskinesia, primary, 45 · score 0.27
- Heterotaxy · score 0.21
- hypospadias · score 0.20
- male infertility · score 0.19
- PHF-tau measurement · score 0.15
3D Structure (10)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|---|---|---|---|
| AF-Q9C0G6-F7 | alphafold | PREDICTED | 87.54 | — |
| AF-Q9C0G6-F6 | alphafold | PREDICTED | 87.24 | — |
| AF-Q9C0G6-F8 | alphafold | PREDICTED | 87.22 | — |
| AF-Q9C0G6-F15 | alphafold | PREDICTED | 86.38 | — |
| AF-Q9C0G6-F5 | alphafold | PREDICTED | 86.24 | — |
| AF-Q9C0G6-F10 | alphafold | PREDICTED | 85.99 | — |
| AF-Q9C0G6-F9 | alphafold | PREDICTED | 85.92 | — |
| AF-Q9C0G6-F12 | alphafold | PREDICTED | 85.87 | — |
Experimental structures are not indexed in MolForge yet — search RCSB PDB for Q9C0G6.
Amino-acid sequence (4158 residues)
MTFRATDSEF DLTNIEEYAE NSALSRLNNI KAKQRVSYVT STENESDTQI LTFRHITKAQ EKTRKRQQPI KLEPLPVLKV YQDHKQPEYI HEQNRFQLMT AGIIKRPVSI AKKSFATSST QFLEHQDAVK KMQIHRPYVE VFSPSPPKLP HTGIGKRGLF GTRSSAYPKY TFHDREEVVK ANIRDPLQII KIIRENEHLG FLYMIPAVPR SSIEYDTYNL KVVSYENINK NDYYTISQRA VTHIYNEDIE FIEIDRWEQE YLYHRELTKI PIFSLFRKWK AFSVWRKNVR SKKITGCQKS LQKNLFIVNP HLRPALLKIN ELCYHLSFMG LCYIEKCHTY TLQEFKAAQV IRLAEVTERL GEFRNEAKYV VRRACRFALR AAGFVPDDCA FGPFEDYHKV QSSGSFINTP HELPTYGDSE KMTYTEQASK RHYCMRLTCF IRLNDYLIEN TMHILTVNAV NSLLNHLTDK LKRTPSADVI QKWITEEKPE VPDKKGTLMV EKQEEDESLI PMFLTELMLT VQSLLFEPSL EDFLDGILGA VNHCQNTVLS VPNLVPDSYF DAFTSPYINN KLEGKTCGTG PSLAAVFEDD KNFHTIISQI KETIQAAFES ARIYAATFEK FQIFFKENES LDLQALKLQE PDINFFSEQL EKYHKQHKDA VALRPTRNVG LLLIDTRLLR EKLIPSPLRC LEVLNFMLPR QSKKKVDAII FEAQDAEYKL EFVPTTTTEY VHSLLFLDEI QERIESLEDE GNIVTQMYKL MEQYQVPTPP EDFAVFATMK PSIVAVRNAI DKSVGDRESS IKQFCVHLGS DLEELNNEVN EVKLQAQDPQ ILDISADQDK IRLILNNLQS VLADLQKRAF QYKSYQKNFK VEVSKFEALE EVSAELKLKQ LLWDSFSEWD KLQQEWLKSK FDCLDPEVLN GQVSKYAKFV TQLEKGLPPN SVVPQLKYKV EKMKEKLPVI IDLRNPTLKA RHWAAIEQTV DATLVDAEIP LTLERLSQLH VFDFGQEIQD ISGQASGEAA LEAILKKVED SWKTTEFVIL PHRDSKDVFI LGGTDDIQVL LDDSTINVAT LASSRYLGPL KTRVDEWQKQ LALFNQTLEE WLTCQRNWLY LESIFNAPDI QRQLPAEAKM FLQVDKSWKE IMRKVNRLPN ALRAATQPGL LETFQNNNAL LDQIQKCLEA YLESKRVIFP RFYFLSNDEL LEILAQTRNP QAVQPHLRKC FDSISKLEFA LMPPAEGKIP GIDGEPEKVY TNDILAMLSP EGERVSLGKG LKARGNVEEW LGKVEEAMFT SLRRLCKAAI ADYQGKLRTD WVVAGHPSQV ILTVSQIMWC RDLTECLETE HSNHIQALKN FEKVNFERLN ALAAIVQGSL PKLHRNILTA LITIDVHARD IVTELVQSKV ETVESFDWQR QLRYYWDIDL DNCVARMALS QYTYGYEYLG ACPRLVITPL TDRCYLCLMG ALQLDLGGAP AGPAGTGKTE TTKDLAKALA IQCVVFNCSD GLDYKMMGRF FSGLAQSGAW CCFDEFNRID IEVLSVIAQQ LITIRNAKAA KLSRFMFEGR EIKLVMTCAA FITMNPGYAG RTELPDNLKA LFRPFAMMVP NYALIAEVIL YSEGFESSKI LARKMTQMYK LCSEQLSQQD HYDFGMRAVK SVLVMAGSLK RENPDLNEDV VLIRALQDSN LPKFLTDDAL LFSGIISDLF PGVQIPEHDY GILQSTIVDV MNRQNLQPEM CMVRKVIQFY ETMLVRHGVM LVGPTGGGKT TVYRILAETL GNLQKLGIEN SFYQAVKTYV LNPKSITMGE LYGEVNNLTL EWKDGLMALS VRAAVNDTSE DHKWIISDGP VDALWIENMN TVLDDNKMLC LANSERIKLT PQIHMLFEVQ DLRVASPATV SRCGMVFVDP EELKWMPYVK TWMKGISKKL TEETQEYILN LFQRYVDEGL HFINKKCSQA IPQVDISKVT TLCCLLESLI LGKDGVNLAM EQTKLNTILC QTFVFCYLWS LGGNLTENYY DSFDTFIRTQ FDDNPDARLP NSGDLWSIHM DFDTKRLDPW ERIIPTFKYN RDVPFFEMLV PTTDTVRYGY LMEKLLAVKH SVLFTGITGV GKSVIAKGLL NKIQESAGYV PVYLNFSAQT SSARTQEIIE SKLERKRKNI LGAPGNKRIV IFVDDLNMPR LDRYGSQPPI ELLRQYQDFG GFYDRNKLFW KEIQDVTIIS ACAPPGGGRN PVTPRFIRHF SMLCLPMPSE HSLKQIFQAI LNGFLSDFPP AVKQTASSIV EASVEIYNKM SVDLLPTPAK SHYVFNLRDL SKCVQGILQC DPGTIREEIQ IFRLFCHECQ RVFHDRLINN EDKHYFHVIL TEMANKHFGI AIDLEYFLNK PIIFGDFIKF GADKADRIYD DMPDIEKTAN VLQDYLDDYN LTNPKEVKLV FFQDAIEHVS RIARMIRQER GNALLVGVGG TGKQSLTRLA AHICGYKCLQ IELSRGYNYD SFHEDLRKLY KMAGVEDKNM VFLFTDTQIV VEEFLEDINN ILNSGEVPNL FEKDELEQVL AATRPRAKEV GISEGNRDEV FQYFISKVRQ KLHIVLCMSP VGEAFRSRCR MFPSLVNCCT IDWFVQWPRE ALLSVSKTFF SQVDAGNEEL KEKLPLMCVN VHLSVSSMAE RYYNELRRRY YTTPTSYLEL INLYLSMLSE KRKQIISARD RVKNGLTKLL ETNILVDKMK LDLSALEPVL LAKSEDVEAL MEKLAVDQES ADQVRNTVQE DEATAKVKAE ETQAIADDAQ RDLDEALPAL DAANKALDSL DKADISEIRV FTKPPDLVMT VMEAISILLN AKPDWPSAKQ LLGDSNFLKR LLEYDKENIK PQILAKLQKY INNPDFVPEK VEKVSKACKS MCMWVRAMDL YSRVVKVVEP KRQKLRAAQA ELDITMATLR EKQALLRQVE DQIQALQDEY DKGVNEKESL AKTMALTKAR LVRAGKLTAA LEDEQVRWEE SIQKFEEEIS NITGNVFIAA ACVAYYGAFT AQYRQSLIEC WIQDCQSLEI PIDPSFSLIN ILGDPYEIRQ WNTDGLPRDL ISTENGILVT QGRRWPLMID PQDQANRWIR NKESKSGLKI IKLTDSNFLR ILENSIRLGL PVLLEELKET LDPALEPILL KQIFISGGRL LIRLGDSDID YDKNFRFYMT TKMPNPHYLP EVCIKVTIIN FTVTKSGLED QLLSDVVRLE KPRLEEQRIK LIVRINTDKN QLKTIEEKIL RMLFTSEGNI LDNEELIDTL QDSKITSGAI KTRLEEAEST EQMINVAREK YRPVATQGSV MYFVIASLSE IDPMYQYSLK YFKQLFNTTI ETSVKTENLQ QRLDVLLEQT LLTAYVNVSR GLFEQHKLIY SFMLCVEMMR QQGTLSDAEW NFFLRGSAGL EKERPPKPEA PWLPTATWFA CCDLEESFPV FHGLTQNILS HPISIRLGSF ETYINPQKWE GYSKMKHEDK HMRQEKEAAH QDPWSAGLSS FHKLILIKCC KEEKVVFALT DFVIENLGKQ FIETPPVDLP TLYQDMSCNT PLVFILSTGS DPMGAFQRFA RESGYSERVQ SISLGQGQGP IAEKMVKDAM KSGNWVFLQN CHLAVSWMLA MEELIKTFTD PDSAIKDTFR LFLSSMPSNT FPVTVLQNSV KVTNEPPKGL RANIRRAFTE MTPSFFEENI LGKKWRQIIF GICFFHAIIQ ERKKFGPLGW NICYEFNDSD RECALLNLKL YCKEGKIPWD ALIYITGEIT YGGRVTDSWD QRCLRTILKR FFSPETLEED YKYSESGIYF APMADSLQEF KDYIENLPLI DDPEIFGMHE NANLVFQYKE TSTLINTILE VQPRSSTGGE GKSNDEIVQE LVASVQTRVP EKLEMEGASE SLFVKDLQGR LNSLTTVLGQ EVDRFNNLLK LIHTSLETLN KAIAGFVVMS EEMEKVYNSF LNNQVPALWS NTAYPSLKPL GSWVKDLILR TSFVDLWLKR GQPKSYWISG FFFPQGFLTG TLQNHARKYN LPIDELSFKY SVIPTYRDQA AVIEAAKTVQ FGQELPMDME LPSPEDGVLV HGMFMDASRW DDKEMVIEDA LPGQMNPVLP VVHFEPQQNY KPSPTLYHCP LYKTGARAGT LSTTGHSTNF VVTVLLPSKR SKDYWIAKGS ALLCQLSE
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
Which diseases are associated with DNAH6?
The strongest Open Targets associations for DNAH6 are Parkinson disease, multiple sclerosis, lysosomal storage disease, neurodegenerative disease and Alzheimer disease.
How long is the DNAH6 protein?
The Homo sapiens DNAH6 protein (UniProt Q9C0G6) is 4158 amino acids long.
Browse: Targets: D · all protein targets A–Z · drugs A–Z.
Sources
- UniProtKB Q9C0G6 — name, gene, function, sequence, keywords (CC BY 4.0)
- AlphaFold DB Q9C0G6 — predicted 3D structure (CC BY 4.0)
- Open Targets Platform — disease associations and tractability (CC0)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.